We are comparing a new treatment, CDR132L, with a placebo for people with heart failure and left ventricular hypertrophy. The goal is to see if it improves heart function and structure better than standard care.
Health conditions and diseases that the clinical trial is designed to study and treat.
Heart Failure with Reduced Ejection Fraction (HFrEF) is a condition where the heart is unable to pump blood effectively due to weakened heart muscles, often accompanied by left ventricular hypertrophy, which is the thickening of the heart's left ventricle.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
